WO2007047607A3 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues - Google Patents

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues Download PDF

Info

Publication number
WO2007047607A3
WO2007047607A3 PCT/US2006/040429 US2006040429W WO2007047607A3 WO 2007047607 A3 WO2007047607 A3 WO 2007047607A3 US 2006040429 W US2006040429 W US 2006040429W WO 2007047607 A3 WO2007047607 A3 WO 2007047607A3
Authority
WO
WIPO (PCT)
Prior art keywords
posterior segment
selectively penetrating
ocular therapy
derivatives selectively
segment tissues
Prior art date
Application number
PCT/US2006/040429
Other languages
French (fr)
Other versions
WO2007047607A2 (en
Inventor
Jeffrey L Edelman
Kelly M Harrison
Original Assignee
Allergan Inc
Jeffrey L Edelman
Kelly M Harrison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Jeffrey L Edelman, Kelly M Harrison filed Critical Allergan Inc
Priority to NZ562032A priority Critical patent/NZ562032A/en
Priority to AU2006304416A priority patent/AU2006304416B2/en
Priority to CA2602577A priority patent/CA2602577C/en
Priority to BRPI0613401A priority patent/BRPI0613401B8/en
Priority to JP2008536724A priority patent/JP5745208B2/en
Priority to MX2007012061A priority patent/MX2007012061A/en
Priority to MX2012007846A priority patent/MX339797B/en
Priority to EP06826056.1A priority patent/EP1937210B1/en
Priority to KR1020077028609A priority patent/KR101430760B1/en
Publication of WO2007047607A2 publication Critical patent/WO2007047607A2/en
Publication of WO2007047607A3 publication Critical patent/WO2007047607A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Ophthalmically therapeutic materials, such, as liquid- containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
PCT/US2006/040429 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues WO2007047607A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ562032A NZ562032A (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
AU2006304416A AU2006304416B2 (en) 2005-10-18 2006-10-17 Ocular therapy using Glucocorticoid Derivatives selectively penetrating posterior segment tissues
CA2602577A CA2602577C (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
BRPI0613401A BRPI0613401B8 (en) 2005-10-18 2006-10-17 ophthalmic composition comprising glucocorticoid derivatives that selectively penetrate posterior segment tissues
JP2008536724A JP5745208B2 (en) 2005-10-18 2006-10-17 Ocular treatment with glucocorticoid derivatives that selectively penetrate the posterior tissue.
MX2007012061A MX2007012061A (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues.
MX2012007846A MX339797B (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues.
EP06826056.1A EP1937210B1 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
KR1020077028609A KR101430760B1 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72820905P 2005-10-18 2005-10-18
US60/728,209 2005-10-18

Publications (2)

Publication Number Publication Date
WO2007047607A2 WO2007047607A2 (en) 2007-04-26
WO2007047607A3 true WO2007047607A3 (en) 2007-11-15

Family

ID=37872252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040429 WO2007047607A2 (en) 2005-10-18 2006-10-17 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Country Status (11)

Country Link
US (5) US8062657B2 (en)
EP (1) EP1937210B1 (en)
JP (2) JP5745208B2 (en)
KR (1) KR101430760B1 (en)
CN (1) CN101394834A (en)
AU (1) AU2006304416B2 (en)
BR (1) BRPI0613401B8 (en)
CA (1) CA2602577C (en)
MX (2) MX2007012061A (en)
NZ (1) NZ562032A (en)
WO (1) WO2007047607A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
EP1937210B1 (en) * 2005-10-18 2017-05-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
PL2214646T3 (en) 2007-10-05 2021-12-20 Wayne State University Dendrimers for sustained release of compounds
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
EP2799448A1 (en) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
CA2785468A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012100142A2 (en) * 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
US10501779B2 (en) * 2011-05-12 2019-12-10 President And Fellows Of Harvard College Oligonucleotide trapping
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013169647A1 (en) 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10369124B2 (en) 2014-04-30 2019-08-06 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
JP6342575B2 (en) 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー Selective dendrimer delivery to brain tumors
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US20180293360A1 (en) * 2015-10-07 2018-10-11 Genentech, Inc. Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CN106983733A (en) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 Triamcinolone acetonide PLGA sustained-release microspheres injections, its preparation method and its application in treatment osteo-arthritic pain medicine is prepared
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661055A1 (en) * 1993-12-31 1995-07-05 Laboratorios Cusi, S.A. Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof
US20020182185A1 (en) * 2000-11-29 2002-12-05 Wong Vernon G. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2004050065A1 (en) * 2002-11-27 2004-06-17 Biosante Pharmaceuticals, Inc. Intraocular delivery compositions and methods
US20040171598A1 (en) * 2003-02-20 2004-09-02 Bingaman David P. Use of steroids to treat persons suffering from ocular disorders
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005107727A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Steroid intraocular implants having an extended sustained release for a period of greater than two months

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0244178A3 (en) 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (en) * 1990-11-30 1999-05-01 요시다 쇼오지 A controlled-release pharmaceutical preparation for intra-ocular implant
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
DE69738935D1 (en) 1996-11-05 2008-10-02 Childrens Medical Center Compositions containing thalidomide and dexamethasone for the treatment of cancer
EP1003569B1 (en) * 1997-08-11 2004-10-20 Allergan, Inc. Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1453914B1 (en) 2001-12-12 2009-03-25 Rhodia Chimie Formulation comprising an anionic compound, a polyionic polymer, and a copolymer
US6873524B2 (en) * 2002-08-15 2005-03-29 Audavi Corporation Data storage device
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
EP1937210B1 (en) 2005-10-18 2017-05-31 Allergan, Inc. Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
JP2007309763A (en) 2006-05-18 2007-11-29 Sumitomo Electric Ind Ltd Surface flaw detector of electric wire

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661055A1 (en) * 1993-12-31 1995-07-05 Laboratorios Cusi, S.A. Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof
US20020182185A1 (en) * 2000-11-29 2002-12-05 Wong Vernon G. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2004050065A1 (en) * 2002-11-27 2004-06-17 Biosante Pharmaceuticals, Inc. Intraocular delivery compositions and methods
US20040171598A1 (en) * 2003-02-20 2004-09-02 Bingaman David P. Use of steroids to treat persons suffering from ocular disorders
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) * 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005107727A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Steroid intraocular implants having an extended sustained release for a period of greater than two months

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 2001 (2001-10-01), WU WEI ET AL: "Intravitreally injectable poly (D, L-lactide) microspheres containing dexamethasone acetate for sustained release", XP002450494, Database accession no. PREV200100555362 *
P.J. MISSEL, L.E. STEVENS, J.W. MAUGER: "Dissolution of Anecortave Acetate in a Cylindrical Flow Cell: Re-Evaluation of Convective Diffusion/Drug Dissolution for Sparingly Soluble Drugs", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 9, no. 4, 2004, pages 453 - 459, XP008083460 *
SILVIA LIGORIO FIALHO ET AL: "MANUFACTURING TECHNIQUES OF BIODEGRADABLE IMPLANTS INTENDED FOR INTRAOCULAR APPLICATION", DRUG DELIVERY, ACADEMIC PRESS, ORLANDO, FL, US, vol. 12, no. 2, April 2005 (2005-04-01), pages 109 - 116, XP009062531, ISSN: 1071-7544 *
YAOXUE XUEBAO, vol. 36, no. 10, October 2001 (2001-10-01), pages 766 - 770, ISSN: 0513-4870 *

Also Published As

Publication number Publication date
AU2006304416A1 (en) 2007-04-26
BRPI0613401B1 (en) 2020-08-04
US9259429B2 (en) 2016-02-16
US20070088014A1 (en) 2007-04-19
US9820995B2 (en) 2017-11-21
CA2602577C (en) 2015-03-31
AU2006304416B2 (en) 2013-03-28
MX2007012061A (en) 2007-12-13
BRPI0613401B8 (en) 2021-05-25
BRPI0613401A2 (en) 2011-01-11
JP2014028855A (en) 2014-02-13
JP2009511632A (en) 2009-03-19
NZ562032A (en) 2011-11-25
EP1937210A2 (en) 2008-07-02
US10188665B2 (en) 2019-01-29
CA2602577A1 (en) 2007-04-26
KR20080055749A (en) 2008-06-19
US20160158249A1 (en) 2016-06-09
MX339797B (en) 2016-06-10
US8062657B2 (en) 2011-11-22
US20180125861A1 (en) 2018-05-10
CN101394834A (en) 2009-03-25
EP1937210B1 (en) 2017-05-31
US20140357609A1 (en) 2014-12-04
JP5745208B2 (en) 2015-07-08
WO2007047607A2 (en) 2007-04-26
US20120065178A1 (en) 2012-03-15
KR101430760B1 (en) 2014-08-19
US8840872B2 (en) 2014-09-23

Similar Documents

Publication Publication Date Title
WO2007047607A3 (en) Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
BRPI0506983A (en) localized eye therapy compositions, preferably comprising triamcinolone acetonide and hyaluronic acid
WO2007100745A3 (en) Apparatus and formulations for suprachoroidal drug delivery
WO2009061607A3 (en) Water-immiscible materials as vehicles for drug delivery
MX2009013832A (en) Purine derivatives and their use as modulators of toll-like receptor 7.
RS20070076A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
EP2279732A3 (en) Compounds and compositions for delivering active agents
BRPI0607483A2 (en) microimplants for ocular administration
WO2011091205A3 (en) Intracameral sustained release therapeutic agent implants
MX2010004373A (en) Non-aqueous water-miscible materials as vehicles for drug delivery.
WO2005034875A3 (en) Method and material for enhance tissue-biomaterial integration
DK2712610T3 (en) Methods for the preparation of cyclic lipid implants for intraocular use
WO2006116591A3 (en) Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
WO2010009111A3 (en) A drug depot implantable within a synovial joint
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
IL179012A (en) Pharmaceutical composition comprising citerizine for the treatment of rhinitis, process for its preparation and uses thereof
RS20070077A (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflamatory diseases
DK2319517T3 (en) APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
WO2007058935A3 (en) Ophthalmic composition for dry eye therapy
WO2004091630A8 (en) Remedies for diseases to be applied to eye
UA92604C2 (en) Stannsoporfin composition having a physiological osmolarity and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680016479.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2602577

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006304416

Country of ref document: AU

Ref document number: 562032

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012061

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 7615/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006304416

Country of ref document: AU

Date of ref document: 20061017

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2006826056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006826056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020077028609

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008536724

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0613401

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080115